此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Interleukine-2 (IL-2) Plus Semaglutide in Alzheimer's Disease

2026年11月3日 更新者:The Methodist Hospital Research Institute

A Phase Ib Clinical Trial, Using Interleukin-2 (IL-2) and Semaglutide in Patients With Alzheimer's Disease

Alzheimer's disease (AD) is the most common cause of dementia. Despite major research efforts, effective treatments that slow or stop disease progression remain limited. Growing evidence suggests that inflammation in the brain and the body plays a key role in the onset and progression of AD. In particular, immune cells called regulatory T cells (Tregs), which normally help control inflammation, are impaired in AD individuals. This leads to increased activity of harmful immune pathways that worsen brain injury. Interleukin-2 (IL-2) is a drug that can restore the function of Tregs. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, are a class of drugs currently used to treat diabetes and obesity. Beyond their metabolic effects, GLP-1RAs also reduce inflammation, protect brain cells, and improve cellular energy balance. Laboratory studies, including our own, show that combining IL-2 with semaglutide has stronger effects than either drug alone. Together, they enhance Treg function, dampen harmful inflammatory responses, and improve cell survival. These findings support testing IL-2 plus semaglutide as a novel combination therapy for AD. We now propose a clinical trial to evaluate the safety, feasibility, and biological effects of this strategy. The study will enroll 30 individuals with AD, ages 50 to 86, who have a confirmed diagnosis by amyloid PET brain imaging and a Mini-Mental State Exam score between 16 and 26. Participants will be randomly assigned to one of three groups: (1) placebo, (2) low-dose IL-2 alone, or (3) IL-2 combined with semaglutide. Throughout the trial, participants will undergo regular medical exams, blood tests, and safety monitoring. We will measure how the treatment affects Tregs and other immune cells, inflammatory markers in blood and CSF, and established Alzheimer's biomarkers such as amyloid beta, tau, and neurofilament light chain. Cognitive and functional assessments will also be conducted to explore potential benefits on memory and daily living skills. If successful, this study will provide the first evidence that a dual immunotherapeutic strategy can safely modify disease-related processes in AD. Such findings would lay the foundation for larger clinical trials and could open the door to a new, multimodal approach to slowing or preventing Alzheimer's progression.

研究概览

研究类型

介入性

注册 (估计的)

30

阶段

  • 阶段2
  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

50年 至 86年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Diagnosis of probable Alzheimer disease according to National Institute on Aging-Alzheimer's Association (NIA-AA) criteria13.
  • Male or female age 50 to 86 years
  • MMSE between 16-26
  • Albumin greater than or equal to 3.0mg/dL
  • White Blood Count (WBC) >3,500/mm3; platelets >100,000/mm3; hematocrit (HCT) >32%.
  • INR<1.4
  • If on medications affecting cognition (rivastigmine, galantamine, donepezil, memantine), participants must be on stable dosage for at least 4 weeks prior to screening and should remain at a stable dosage during the course of the study.
  • English language speaking
  • Formal education of eight or more years
  • Stable pharmacological treatment of any other chronic conditions for at least 30 days prior to screening
  • A family member or caretaker who is expected to be consistently available, administer study drugs of IL-2 and attend study visits throughout the study.
  • For AD patients with limited decision-making capacity, the legally authorized representative (LAR) should be present and consent based on the patient's best interest.

Exclusion Criteria:

  • Any untreated bacterial, fungal or viral infection

  • Renal dysfunction indicated by serum creatinine greater than 1.5 mg/dL

  • Hepatic impairment indicated by Alanine aminotransferase level (ALT) and aspartate aminotransferase (AST) greater than two times normal

  • Clinically significant pulmonary dysfunction, including a history of chronic pulmonary disease (e.g., chronic obstructive pulmonary disease [COPD]) associated with functional limitation, or FEV₁ < 75% of predicted for age and height when pulmonary function testing indicated to evaluate ongoing respiratory symptoms

  • Clinically significant cardiac dysfunction, including a history of uncontrolled cardiac arrhythmias, prior cardiac tamponade, or unstable angina or myocardial infarction within 3 months prior to screening, or clinically significant abnormalities on baseline electrocardiogram (ECG). LVEF< 40% in echocardiography if clinically indicated based on ongoing cardiac symptoms or abnormal ECG findings

  • Hypersensitivity or allergy to IL-2

  • History of severe gastrointestinal disease Hospitalization or change of chronic concomitant medication within one month prior to screening.

  • History of hemorrhage or infarct or > 3 lacunar infarcts, cerebral contusion, encephalomalacia, aneurysm, vascular malformation, subdural hematoma, hydrocephalus, space-occupying lesion (e.g., abscess or brain tumor with the exception of small incidental meningiomas) in prior CT or MRI.

  • Clinical or laboratory findings consistent with:

    1. Other primary degenerative dementia, (dementia with Lewy bodies, fronto-temporal dementia, Huntington's disease, Creutzfeld-Jakob Disease(CJD), Down's syndrome, etc.)
    2. Other neurodegenerative condition (Parkinson's disease, amyotrophic lateral sclerosis, etc.)
    3. Seizure disorder
    4. History of infectious, metabolic or systemic diseases affecting the central nervous system (syphilis, vitamin B12 or folate deficiency, other laboratory values, etc.)
    5. Clinically significant abnormal T4 or TSH
  • Clinically significant, advanced or unstable disease that may interfere with outcome evaluations, such as:

    1. Respiratory insufficiency
    2. Bradycardia (<45/min.) or tachycardia (>100/min.)
    3. Poorly managed hypertension (systolic >160 mm Hg and/or diastolic >95 mm Hg) or hypotension (systolic <90 mm Hg and/or diastolic <60 mm Hg)
    4. Uncontrolled diabetes defined by HbA1c >8%
  • History of cancer within 3 years of screening with the exception of fully excised non-melanoma skin cancers or non-metastatic prostate cancer that has been stable for at least 6 months.

  • History of acute/chronic hepatitis B or C and/or carriers of hepatitis B

  • History of organ allografts

  • Current treatment with insulin or insulin secretagogues (including sulfonylureas or meglitinides)

  • Prior GLP-1 RA administration or natural GLP1 supplements intake within the past 6 months

  • Disability that may prevent the patient from completing all study requirements (e.g., blindness, deafness, severe language difficulty, etc.).

  • Within 4 weeks of screening visit or during the course of the study, concurrent treatment with antipsychotic agents (except risperidone ≤1.5 mg/day, quetiapine ≤100 mg/day, olanzapine ≤5 mg/day, and aripiprazole ≤10 mg/day), antiepileptics (except lamotrigine, gabapentin and pregabalin for nonseizure indications), centrally active anti-hypertensive drugs (e.g., clonidine, l-methyl dopa, guanidine, guanfacine, etc.), opiate analgesics, systemic corticosteroids, psychostimulants, antiparkinsonian medications (except for non-parkinsonian indications) and mood stabilizers (e.g., valproate, lithium), sedatives, and anxiolytics with the exception that use of short- to medium-acting benzodiazepines for treatment of insomnia is permitted, however, use of sedatives or hypnotics should be avoided for 8 hours before administration of cognitive tests.

  • Nootropic drugs except stable AD meds (acetylcholinesterase inhibitors and memantine.

  • Use of concomitant CYP-metabolized medications with a narrow therapeutic index including warfarin, calcineurin inhibitors, or theophylline)

  • Suspected or known drug or alcohol abuse, i.e., more than approximately 60 g alcohol (approximately 1 liter of beer or 0.5 liter of wine) indicated by elevated MCV significantly above normal value at screening

  • Suspected or known allergy to any components of the study treatments.

  • Intake of investigational drug within the previous 30 days or five half-lives of the investigational drug, whichever is longer.

  • Contraindication to undergoing an LP including, but not limited to: inability to tolerate an appropriately flexed position for the time necessary to perform an LP; INR >1.4 or other coagulopathy; platelet count of <100,000/μL; infection at the desired lumbar puncture site; taking anti-coagulant medication within 90 days of screening (Note: low dose aspirin is permitted); suspected non-communicating hydrocephalus or intracranial mass; prior history of spinal mass or trauma.

  • Any condition, which in the opinion of the investigator makes the patient unsuitable for inclusion.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
安慰剂比较:Placebo

Placebo Administration

Placebo

有源比较器:Low-dose recombinant human IL-2 (LD IL-2) monotherapy

Low-dose recombinant human IL-2 (LD IL-2) monotherapy (aldesleukin) administered subcutaneously once daily for 5 consecutive days, repeated every 4 weeks for six cycles.

aldesleukin administered subcutaneously once daily for 5 consecutive days, repeated every 4 weeks for six cycles

有源比较器:IL-2 Plus Semaglutide combination therapy

Combination therapy with LD IL-2 on the same schedule as Arm B plus subcutaneous semaglutide, administered with stepwise dose escalation administered once weekly

Combination therapy with LD IL-2 plus subcutaneous semaglutide

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Evaluate the Incidence of Treatment-Emergent Adverse Events of IL-2 plus Semaglutide in AD patients
大体时间:6 months treatment phase

Number of participants with adverse events and with abnormal laboratory findings (serum chemistry, hematology).

6 months treatment phase

次要结果测量

结果测量
措施说明
大体时间
The impact of IL-2 plus Semaglutide administration on the blood Treg population
大体时间:6 months treatment phase

Change in Treg percentage out of total # of CD4 cells from baseline to month 6

6 months treatment phase

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年9月1日

初级完成 (估计的)

2029年6月1日

研究完成 (估计的)

2029年12月1日

研究注册日期

首次提交

2026年6月2日

首先提交符合 QC 标准的

2026年6月10日

首次发布 (实际的)

2026年6月16日

研究记录更新

最后更新发布 (实际的)

2026年11月6日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅